Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Recro Pharma reports inducement grants for new staff » 07:07
04/06/21
04/06
07:07
04/06/21
07:07
REPH

Recro Pharma

$3.00 /

+ (+0.00%)

Recro Pharma announced…

Recro Pharma announced the expansion of its team through the addition of new employees primarily in the areas of analytical development, business development, sales and marketing to support our continued growth and customer diversification efforts. In connection with the hiring of these personnel, the compensation committee of Recro's board of directors approved inducement stock option grants to purchase an aggregate of 98,843 shares of Recro's common stock. The equity awards were granted pursuant to the NASDAQ inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with Recro in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards were granted on March 31, 2021 and will have an exercise price equal to the closing price of Recro's common stock on March 31, 2021. The options have a ten-year term and vest in equal monthly installments over four years. The equity awards are subject to each individual's continued service with Recro through the applicable vesting dates.

ShowHide Related Items >><<
REPH Recro Pharma
$3.00 /

+ (+0.00%)

REPH Recro Pharma
$3.00 /

+ (+0.00%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$3.00 /

+ (+0.00%)

Hot Stocks
Recro Pharma adds six members to business development team » 07:11
04/05/21
04/05
07:11
04/05/21
07:11
REPH

Recro Pharma

$3.00 /

+0.23 (+8.30%)

Recro Pharma announced…

Recro Pharma announced significant recent progress in strengthening the company's business development team to support its strategic objective of expanding and diversifying its customer base. In recent months, the company has added six new members to its business development team, including sales representatives for its emerging Clinical Trial Services business, as well as regional representatives bolstering the company's reach in critical life science markets in Northern and Southern California, Boston and the Midwest. With these additions, Recro's current business development team is comprised of 11 experienced professionals, led by longtime global sales and marketing executive, William Hirschman. The efforts of the expanded team have already driven considerable growth for Recro's customer base during the first quarter of 2021, both through the expansion of the scope of work for several current customers, as well as the onboarding of a number of new customers.

ShowHide Related Items >><<
REPH Recro Pharma
$3.00 /

+0.23 (+8.30%)

REPH Recro Pharma
$3.00 /

+0.23 (+8.30%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$3.00 /

+0.23 (+8.30%)

Over a month ago
Hot Stocks
Baudax Bio appoints Richard Casten as CFO » 07:12
03/08/21
03/08
07:12
03/08/21
07:12
BXRX

Baudax Bio

$1.22 /

+0.025 (+2.09%)

, REPH

Recro Pharma

$3.28 /

-0.365 (-10.03%)

Baudax Bio (BXRX)…

Baudax Bio (BXRX) announced the appointment of Richard Casten, CPA, MBA as CFO. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. He replaces Ryan Lake, CPA who is transitioning to full time CFO for Recro (REPH). Prior to joining Baudax, Mr. Casten served as Vice President of Finance, Controller and Treasurer at Lupin Pharmaceuticals. In connection with the hiring of Mr. Casten, the Compensation Committee of Baudax Bio's Board of Directors approved an inducement grant of stock options to purchase an aggregate of 270,000 shares of Baudax Bio's common stock and restricted stock units covering 100,000 shares of Baudax Bio's common stock, with a grant date of March 8, 2021. The equity award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Casten's employment compensation and was granted as an inducement material to his acceptance of employment with Baudax Bio. The options have an exercise price equal to the closing price of Baudax Bio's common stock as reported by Nasdaq on March 8, 2021. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying the stock option vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly over 36 months thereafter. The restricted stock units vest annually over four years. The equity award is subject to Mr. Casten's continued service with Baudax Bio through the applicable vesting dates.

ShowHide Related Items >><<
REPH Recro Pharma
$3.28 /

-0.365 (-10.03%)

BXRX Baudax Bio
$1.22 /

+0.025 (+2.09%)

BXRX Baudax Bio
$1.22 /

+0.025 (+2.09%)

05/15/20 JMP Securities
Baudax Bio initiated with an Outperform at JMP Securities
REPH Recro Pharma
$3.28 /

-0.365 (-10.03%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$3.28 /

-0.365 (-10.03%)

BXRX Baudax Bio
$1.22 /

+0.025 (+2.09%)

  • 24
    Mar
Earnings
Recro Pharma sees Q1 revenue up approx. 65%-70% vs. Q4, two est. $17.64M » 07:44
02/26/21
02/26
07:44
02/26/21
07:44
REPH

Recro Pharma

$4.93 /

-0.115 (-2.28%)

CEO David Enloe said,…

CEO David Enloe said, "While there is more work to do, we are confident that these strategic initiatives will position Recro for significant growth in the future. Looking to 2021, we believe these efforts have already had a positive impact. Specifically, we expect revenues for Q1 2021 to increase by approximately 65 -70% as compared to Q4 2020 revenues, and for the full year 2021, we expect to outpace growth in the small molecule drug sector as a whole. In closing, it is important to note that transitions and reorganizations are not easy for any company. Throughout this repositioning of Recro's mission and purpose, I have been incredibly impressed with the commitment of the entire Recro team. Their commitment to our customer's success and to providing high quality products is cause for me to be very optimistic for Recro's future."

ShowHide Related Items >><<
REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

Hot Stocks
Recro Pharma initiates reorganization to enhance operations » 07:43
02/26/21
02/26
07:43
02/26/21
07:43
REPH

Recro Pharma

$4.93 /

-0.115 (-2.28%)

"In 2020, our…

"In 2020, our top-line revenues and margins were impacted by the return of a competitor's manufacturing capacity which had been offline in 2019, headwinds created by sharply reduced prescriptions written for the largest products in our portfolio due to the Covid-19 pandemic, and variability in customer ordering patterns. Looking ahead, since joining Recro in mid-December, my priority has been to carefully evaluate our organization's vulnerabilities and opportunities for improvement, and to swiftly develop an executable strategy which sets us on a path to become a strong, trusted CDMO partner capable of achieving meaningful and sustainable growth," said David Enloe, president and CEO. "To achieve our goals for growth, our team recently launched a four-pronged strategy that we believe will significantly strengthen the business in the coming quarters. This strategy calls for expansion and diversification of Recro's customer base; strengthening of our balance sheet position in order to better support both organic and inorganic growth; augmentation of our leadership as well as restructuring our operational organization and finally, continuing to upgrade and expand our facilities and capabilities to support growing customer demand. With respect to top-line growth, our strategy is to mitigate revenue variability and vulnerability by continuing to increase the number of customers we have, as well as to evaluate our portfolio to ensure we have projects across the biopharma life cycle curve. To that end, in the second quarter of 2020, Recro added clinical trial support services to its early GMP-centered offerings to augment our existing customer portfolio. This business is nascent, but we've been successful in the last few months building our visibility in this segment and onboarding multiple clinical stage customers. While this new business represents a high-value revenue channel for Recro, our core commercial business remains strong, and we continue to pursue opportunities to further support our existing customers. At present, nearly half of our existing clinical trial materials customers either have expanded or are in the process of expanding their programs beyond the initial scope of work. To continue this trajectory, we have been augmenting our business development team to ensure we are best positioned to identify the types of programs where Recro can partner to create the best value for our customers and ourselves. The second component of our strategy is to strengthen our balance sheet in order to be better positioned for both organic and inorganic growth. We were very pleased to announce earlier this week that we significantly restructured the debt instrument with our finance partner, Athyrium. As noted in that release, we believe the reduction in the interest rate and a portion of the outstanding debt balance in exchange for equity at market rate, and raising of our net debt to EBITDA covenant, to be a demonstration of the confidence Athyrium has in Recro's success trajectory. The third prong of our strategy is to augment our organization, both in terms of meaningful CDMO leadership as well as a structure for success. Since arriving a few weeks ago, we have brought CDMO specific strength to our leadership team as well as our technical staff. This includes the appointments of James Miller, a highly-regarded CDMO thought leader to our board, and Ryan Lake as our dedicated CFO. We also reorganized our operational leadership structure to streamline our efforts, optimize efficiencies, improve our project management competencies and ensure the strong management and quality practices we have in our commercial business are equally deployed across the growing clinical trial materials business. Finally, the fourth prong of our growth strategy focuses on the enhancement of our facilities and capabilities. Hand-in-hand with our plan to service an expanding customer base, we are committed to putting the systems and processes in place to support a broad development and manufacturing portfolio. To that end, two new manufacturing suites were recently constructed and commissioned to support the technical transfer and planned validation activities for several new commercial programs. We are pleased to report that the analytical transfers for these programs have been successfully completed and validation batches will begin in March."

ShowHide Related Items >><<
REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

Earnings
Recro Pharma reports Q4 EPS (48c), two est. (25c) » 07:40
02/26/21
02/26
07:40
02/26/21
07:40
REPH

Recro Pharma

$4.93 /

-0.115 (-2.28%)

Reports Q4 revenue $9.9M,…

Reports Q4 revenue $9.9M, two est. $15M.

ShowHide Related Items >><<
REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$4.93 /

-0.115 (-2.28%)

Conference/Events
Recro Pharma management to meet virtually with William Blair » 04:55
02/23/21
02/23
04:55
02/23/21
04:55
REPH

Recro Pharma

$4.90 /

+0.3398 (+7.45%)

Virtual Meetings to be…

Virtual Meetings to be held February 22-23 hosted by William Blair.

ShowHide Related Items >><<
REPH Recro Pharma
$4.90 /

+0.3398 (+7.45%)

REPH Recro Pharma
$4.90 /

+0.3398 (+7.45%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$4.90 /

+0.3398 (+7.45%)

Conference/Events
Recro Pharma management to meet virtually with William Blair » 11:23
02/22/21
02/22
11:23
02/22/21
11:23
REPH

Recro Pharma

$4.80 /

+0.24 (+5.26%)

Virtual Meetings to be…

Virtual Meetings to be held February 22-23 hosted by William Blair.

ShowHide Related Items >><<
REPH Recro Pharma
$4.80 /

+0.24 (+5.26%)

REPH Recro Pharma
$4.80 /

+0.24 (+5.26%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$4.80 /

+0.24 (+5.26%)

Hot Stocks
Recro Pharma announces key appointments in management team » 07:26
02/11/21
02/11
07:26
02/11/21
07:26
REPH

Recro Pharma

$4.14 /

+0.08 (+1.97%)

Recro Pharma announced…

Recro Pharma announced the continued strengthening of its leadership through key appointments to its management team and board of directors. Recro named James Miller, a highly regarded CDMO industry thought leader, to its board of directors. Additionally, the company appointed Ryan D. Lake, who possesses more than 20 years of senior financial and life sciences experience, as CFO, in late 2020. These additions, along with the appointment of David Enloe as CEO in late 2020, highlight the company's ongoing commitment to build a world-class leadership team of experienced CDMO industry veterans best positioned to drive significant growth for Recro's differentiated business within the rapidly expanding manufacturing services market. Miller is a well-known and highly regarded advisor on drug manufacturing strategy and a pre-eminent authority on the biopharmaceutical CDMO industry. He is founder and former president of PharmSource, the CDMO industry's principal source of market intelligence, which was sold to Global Data, a London-based, publicly-traded provider of market intelligence services in 2016.

ShowHide Related Items >><<
REPH Recro Pharma
$4.14 /

+0.08 (+1.97%)

REPH Recro Pharma
$4.14 /

+0.08 (+1.97%)

01/04/21 Craig-Hallum
Recro Pharma initiated with a Buy at Craig-Hallum
05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$4.14 /

+0.08 (+1.97%)

Over a quarter ago
Initiation
Recro Pharma initiated with a Buy at Craig-Hallum » 07:49
01/04/21
01/04
07:49
01/04/21
07:49
REPH

Recro Pharma

$2.85 /

-0.075 (-2.56%)

Craig-Hallum analyst Matt…

Craig-Hallum analyst Matt Hewitt initiated coverage of Recro Pharma with a Buy rating and $6 price target. The analyst views Recro Pharma as an "undiscovered and underappreciated turnaround story." While one-time headwinds have weighed on results, Hewitt believes seeds have been planted that are starting to bear fruit for the company.

ShowHide Related Items >><<
REPH Recro Pharma
$2.85 /

-0.075 (-2.56%)

REPH Recro Pharma
$2.85 /

-0.075 (-2.56%)

05/12/20 Oppenheimer
Recro Pharma price target lowered to $12 from $18 at Oppenheimer
REPH Recro Pharma
$2.85 /

-0.075 (-2.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.